Picking the point of inhibition: A comparative review of PI3K/AKT/mTOR pathway inhibitors

Molecular Cancer Therapeutics

Volumn 13, Issue 5, 2014, Pages 1021-1031

  Dienstmann, Rodrigo ^a   Rodon, Jordi ^a   Serra, Violeta ^a   Tabernero, Josep ^a  

^a HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIMITOTIC AGENT; ANTINEOPLASTIC AGENT; B RAF KINASE; K RAS PROTEIN; MAMMALIAN TARGET OF RAPAMYCIN; MAMMALIAN TARGET OF RAPAMYCIN INHIBITOR; P110ALPHA INHIBITOR; P110BETA INHIBITOR; P110DELTA INHIBITOR; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHATIDYLINOSITOL 3 KINASE INHIBITOR; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PROTEIN; PROTEIN KINASE B; PROTEIN KINASE B INHIBITOR; PROTEIN KINASE LKB1; TUBERIN; TUBEROUS SCLEROSIS COMPLEX 1; UNCLASSIFIED DRUG; ISOENZYME; PROTEIN KINASE INHIBITOR; TARGET OF RAPAMYCIN KINASE;

BREAST CANCER; CANCER CELL LINE; CANCER INHIBITION; CANCER RECURRENCE; CANCER SURVIVAL; CASTRATION RESISTANT PROSTATE CANCER; CELL SURVIVAL; CHRONIC LYMPHATIC LEUKEMIA; COLORECTAL CANCER; COWDEN SYNDROME; DRUG EFFICACY; DRUG POTENTIATION; DRUG SAFETY; ENDOMETRIUM CANCER; FEBRILE NEUTROPENIA; GLIOBLASTOMA; HETEROZYGOSITY LOSS; HUMAN; HYPERGLYCEMIA; LARGE CELL LYMPHOMA; LIVER CELL CARCINOMA; LUNG NON SMALL CELL CANCER; MANTLE CELL LYMPHOMA; MELANOMA; MISSENSE MUTATION; NEUTROPENIA; NONHODGKIN LYMPHOMA; NONHUMAN; NONSENSE MUTATION; OVARY CANCER; PANCREAS CANCER; PNEUMONIA; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; REVIEW; SIGNAL TRANSDUCTION; THROMBOCYTOPENIA; TREATMENT DURATION; TUBEROUS SCLEROSIS; TUBEROUS SCLEROSIS COMPLEX; ANIMAL; ANTAGONISTS AND INHIBITORS; DRUG EFFECTS; METABOLISM; NEOPLASMS;

ANIMALS; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; HUMANS; ISOENZYMES; NEOPLASMS; PHOSPHATIDYLINOSITOL 3-KINASES; PROTEIN KINASE INHIBITORS; PROTO-ONCOGENE PROTEINS C-AKT; SIGNAL TRANSDUCTION; TOR SERINE-THREONINE KINASES;

EID: 84899850988     PISSN: 15357163     EISSN: 15388514     Source Type: Journal    
DOI: 10.1158/1535-7163.MCT-13-0639     Document Type: Review

References (86)

1. Weigelt B, Downward J. Genomic determinants of PI3K pathway inhibitor response in cancer. Front Oncol 2012;2:109.
2. Engelman JA, Luo J, Cantley LC. The evolution of phosphatidylinositol 3-kinases as regulators of growth and metabolism. Nat Rev Genet 2006;7:606-19.
3. Serra V, Markman B, Scaltriti M, Eichhorn PJ, Valero V, Guzman M, et al. NVP-BEZ235, a dual PI3K/mTOR inhibitor, prevents PI3K signaling and inhibits the growth of cancer cells with activating PI3K mutations. Cancer Res 2008;68:8022-30.
4. Wallin JJ, Edgar KA, Guan J, Berry M, PriorWW,Lee L, et al. GDC-0980 is a novel class I PI3K/mTOR kinase inhibitor with robust activity in cancer models driven by the PI3K pathway. Mol Cancer Ther 2011; 10:2426-36.
5. Ogita S, Lorusso P. Targeting phosphatidylinositol 3 kinase (PI3K)-Akt beyond rapalogs. Target Oncol 2011;6:103-17.
6. Maira SM, Pecchi S, Huang A, Burger M, Knapp M, Sterker D, et al. Identification and characterization of NVP-BKM120, an orally available pan-class I PI3-kinase inhibitor. Mol Cancer Ther 2012;11: 317-28.
7. O'Brien C, Wallin JJ, Sampath D, GuhaThakurta D, Savage H, Punnoose EA, et al. Predictive biomarkers of sensitivity to the phosphatidylinositol 30 kinase inhibitor GDC-0941 in breast cancer preclinical models. Clin Cancer Res 2010;16:3670-83.
8. Bendell JC, Rodon J, Burris HA, de Jonge M, Verweij J, Birle D, et al. Phase I, dose-escalation study of BKM120, an oral pan-Class I PI3K inhibitor, in patients with advanced solid tumors. J Clin Oncol 2012; 30:282-90.
9. Von Hoff DD, LoRusso P, Demetri GD, Weiss GJ, Shapiro G, Ramanathan RK, et al. A phase I dose-escalation study to evaluate GDC-0941, a pan-PI3K inhibitor, administered QD or BID in patients with advanced or metastatic solid tumors. J Clin Oncol 2011;29: 15s.
10. Rodon J, Burris HA, Schellens JHM, Schuler M, Goodman O, Britten C, et al. Phase I dose-escalation study of the oral dual mTOR/PI3K inhibitor BEZ235, solid dispersion system (SDS) sachet formulation, in patients with advanced solid tumors. Eur J Cancer 2012;48:112.
11. Komiya T, Blumenthal G, Ballas M, Dechowdhury R, Manu M, Fioravanti S, et al. A pilot study of sirolimus (S) in subjects with Cowden syndrome (CS) with germ-line mutations in PTEN. J Clin Oncol 31, 2013 (suppl; abstr 2532).
12. Schwartz RA, Fernandez G, Kotulska K, Jozwiak S. Tuberous sclerosis complex: advances in diagnosis, genetics, and management. J Am Acad Dermatol 2007;57:189-202.
13. Franz DN. Everolimus: an mTOR inhibitor for the treatment of tuberous sclerosis. Expert Rev Anticancer Ther 2011;11:1181-92.
14. Pymar LS, Platt FM, Askham JM, Morrison EE, Knowles MA. Bladder tumour-derived somatic TSC1 missense mutations cause loss of function via distinct mechanisms. Hum Mol Genet 2008;17:2006-17.
15. Iyer G, Hanrahan AJ, Milowsky MI, Al-Ahmadie H, Scott SN, Janakiraman M, et al. Genome sequencing identifies a basis for everolimus sensitivity. Science 2012;338:221.
16. Sanchez-Cespedes M, Parrella P, Esteller M, Nomoto S, Trink B, Engles JM, et al. Inactivation of LKB1/STK11 is a common event in adenocarcinomas of the lung. Cancer Res 2002;62:3659-62.
17. Ji H, Ramsey MR, Hayes DN, Fan C, McNamara K, Kozlowski P, et al. LKB1 modulates lung cancer differentiation and metastasis. Nature 2007;448:807-10.
18. Mahoney CL, Choudhury B, Davies H, Edkins S, Greenman C, Haaften G, et al. LKB1/KRAS mutant lung cancers constitute a genetic subset of NSCLC with increased sensitivity to MAPK and mTOR signalling inhibition. Br J Cancer 2009;100:370-5.
19. Huang X, Wullschleger S, Shpiro N, McGuire VA, Sakamoto K, Woods YL, et al. Important role of the LKB1-AMPK pathway in suppressing tumorigenesis in PTEN-deficient mice. Biochem J 2008;412:211-21.
20. Garcia-Martinez JM, Wullschleger S, Preston G, Guichard S, Fleming S, Alessi DR, et al. Effect of PI3K- and mTOR-specific inhibitors on spontaneous B-cell follicular lymphomas in PTEN/LKB1-deficient mice. Br J Cancer 2011;104:1116-25.
21. Peyton JD, Rodon Ahnert J, Burris H, Britten C, Chen LC, Tabernero J, et al. A dose-escalation study with the novel formulation of the oral pan-class I PI3K inhibitor BEZ235, solid dispersion system (SDS) sachet, in patients with advanced solid tumors. J Clin Oncol 29: 2011 (suppl; abstr 3066).
22. Wagner AJ, Bendell JC, Dolly S, Morgan JA, Ware JA, Fredrickson J, et al. A first-in-human phase I study to evaluate GDC-0980, an oral PI3K/mTOR inhibitor, administered QDin patients with advanced solid tumors. J Clin Oncol 2011;29:15s, (suppl; abstr 3020).
23. Yardley D, Linda D, Bosserman L, Walker-Peacock N, Favret A, Morgan S, Priego V, et al. Everolimus with paclitaxel plus bevacizumab as first-line therapy for HER2-negative metastatic breast cancer (MBC): A randomized, double-blind, placebo-controlled phase II trial of the Sarah Cannon Research Institute (SCRI). J Clin Oncol 30, 2012 (suppl; abstr 1018).
24. Dirix L, Schuler M, Machiels J, Hess D, Awada A, Steeghs N, et al. Phase Ib dose-escalation study of BEZ235 or BKM120 in combination with paclitaxel (Ptx) in patients with advanced solid tumors. Ann Oncol 2012;23:ix157-ix158 (abstr 454P).
25. Wallin JJ, Guan J, Prior WW, Lee LB, Berry L, Belmont LD, et al. GDC- 0941, a novel class I selective PI3K inhibitor, enhances the efficacy of docetaxel in human breast cancer models by increasing cell death in vitro and in vivo. Clin Cancer Res 2012;18:3901-11.
26. Jia S, Roberts TM, Zhao JJ. Should individual PI3 kinase isoforms be targeted in cancer? Curr Opin Cell Biol 2009;21:199-208.
27. Boyd LK, Mao X, Lu YJ. The complexity of prostate cancer: genomic alterations and heterogeneity. Nat Rev Urol 2012;9:652-64.
28. Zardavas D, Baselga J, Piccart M. Emerging targeted agents in metastatic breast cancer. Nat Rev Clin Oncol 2013;10:191-210.
29. Cheung LW, Hennessy BT, Li J, Yu S, Myers AP, Djordjevic B, et al. High frequency of PIK3R1 and PIK3R2 mutations in endometrial cancer elucidates a novel mechanism for regulation of PTEN protein stability. Cancer Discov 2011;1:170-85.
30. Huang A, Fritsch C, Wilson C, Reddy A, Liu M, Lehar J, et al. Single agent activity of PIK3CA inhibitor BYL719 in a broad cancer cell line panel. Cancer Res 2012;72:3749.
31. Sun Y, Dey P, Wu H, Leyland-Jones B. P110 a-specific inhibitor is more suitable in PIK3CA mutated breast cancer model but ineffective in PTEN loss of function breast cancer model. Cancer Res 2012;72:2227.
32. Gonzalez-Angulo A, Juric D, Argiles G, Schellens J, Burris H, Berlin J, et al. Safety, pharmacokinetics, and preliminary activity of the a-specific PI3K inhibitor BYL719: Results from the first-in-human study. J Clin Oncol 31: 2013 (suppl; abstr 2531).
33. Juric D, Krop I,Ramanathan R, Xiao J, Sanabria S, Wilson T, et al. GDC- 0032, a beta isoform-sparing PI3K inhibitor: results of a first-in-human phase Ia dose escalation study. Cancer Res 2013;73:LB-64.
34. Hancox U, Cosulich S, Dry H, Hanson L, Crafter C, Barlaam B, et al. AZD8186: a potent selective inhibitor of PI3Kb targeting PTEN-deficient tumours dependent on dysregulated PI3Kb signalling. Cancer Res 2013;73:3264.
35. Ni J, Liu Q, Xie S, Carlson C, Von T, Vogel K, et al. Functional characterization of an isoform-selective inhibitor of PI3K-p110beta as a potential anticancer agent. Cancer Discov 2012;2:425-33.
36. Edgar KA, Wallin JJ, Berry M, Lee LB, Prior WW, Sampath D, et al. Isoform-specific phosphoinositide 3-kinase inhibitors exert distinct effects in solid tumors. Cancer Res 2010;70:1164-72.
37. Weigelt B, Warne PH, Lambros MB, Reis-Filho JS, Downward J. PI3K pathway dependencies in endometrioid endometrial cancer cell lines. Clin Cancer Res 2013;19:3533-44.
38. Stengel C, Jenner E, Meja K, Mayekar S, Khwaja A. Proliferation of PTEN-deficient haematopoietic tumour cells is not affected by isoform- selective inhibition of p110 PI3-kinase and requires blockade of all class 1 PI3K activity. Br J Haematol 2013;162:285-9.
39. Rivero RA, Hardwicke MA. Identification of GSK2636771, a potent and selective, orally bioavailable inhibitor of phosphatidylinositol 3-kinasebeta (PI3Kb) for the treatment of PTEN deficient tumors. Cancer Res 2012;72:2913.
40. Bouabdallah K, Ribrag V, Terriou L, Soria JC, Delarue R. Temsirolimus in the treatment of mantle cell lymphoma: frequency and management of adverse effects. Curr Opin Oncol 2013;25:S1-12.
41. Furman RR, Byrd JC, Flinn IW, Coutre SE, Benson DM, Brown JR, et al. Interim results from a phase I study of CAL-101, a selective oral inhibitor of phosphatidylinositol 3-kinase p110d isoform, in patients with relapsed or refractory hematologic malignancies. J Clin Oncol 28:15s, 2010 (suppl; abstr 3032).
42. Brown J, Furman R, Flinn I, Coutre S, Wagner-Johnston N, Kahl B, et al. Final results of a phase I study of idelalisib (GS-1101) a selective inhibitor of PI3Kd, in patients with relapsed or refractory CLL. J Clin Oncol 73: 2013 (suppl; abstr 7003).
43. Iyengar S, Clear A, Bodor C, Maharaj L, Lee A, Calaminici M, et al. P110alpha mediated constitutive PI3K signaling limits the efficacy of p110delta-selective inhibition in mantle cell lymphoma, particularly with multiple relapse. Blood 2013;121:2274-84.
44. Martin-Sanchez E, Rodriguez-Pinilla SM, Sanchez-Beato M, Lombardia L, Dominguez-Gonzalez B, Romero D, et al. Simultaneous inhibition of pan-phosphatidylinositol-3-kinases and MEK as a potential therapeutic strategy in peripheral T-cell lymphomas. Haematologica 2013;98:57-64.
45. Amrein L, Shawi M, Grenier J, Aloyz R, Panasci L. The phosphatidylinositol- 3 kinase I inhibitor BKM120 induces cell death in Bchronic lymphocytic leukemia cells in vitro. Int J Cancer 2013; 133:247-52.
46. Fruman DA, Rommel C. PI3Kdelta inhibitors in cancer: rationale and serendipity merge in the clinic. Cancer Discov 2011;1:562-72.
47. Papadopoulos K, Abrisqueta P, Chambers G, Rasco D, Patnaik A, Tabernero J, et al. A phase I dose expansion cohort study of the safety, pharmacokinetics and pharmacodynamics of SAR245409 (S09), an orally administered PI3K/mTOR inhibitor, in patients with lymphoma. Blood 2011;118:1608.
48. Brown J, Davids M, Rodon J, Abrisqueta P, DeCillis A, Rockich K, et al. Phase I trial of SAR245408 (S08), a pan-phosphatidylinositol 3 kinase (PI3K) inhibitor, in patients with Chronic Lymphocytic Leukemia (CLL) and lymphoma. Blood 2011;118:2683.
49. Okkenhaug K, Bilancio A, Farjot G, Priddle H, Sancho S, Peskett E, et al. Impaired B and T cell antigen receptor signaling in p110delta PI 3- kinase mutant mice. Science 2002;297:1031-4.
50. Coutre SE, Byrd JC, Furman RR, Brown JR, Benson DM, Wagner- Johnston ND, et al. Phase I study of CAL-101, an isoform-selective inhibitor of phosphatidylinositol 3-kinase P110d, in patients with previously treated chronic lymphocytic leukemia. J Clin Oncol 2011;29:15s, (suppl; abstr 6631).
51. Juric D, Rodon J, Gonzalez-Angulo AM, Burris HA, Bendell J, Berlin JD, et al. BYL719, a next generation PI3K alpha specific inhibitor: Preliminary safety, PK, and efficacy results from the first-in-human study. Cancer Res 2012;72: Suppl 1:CT-01.
52. Foukas LC, Claret M, Pearce W, Okkenhaug K, Meek S, Peskett E, et al. Critical role for the p110alpha phosphoinositide-3-OHkinase in growth and metabolic regulation. Nature 2006;441:366-70.
53. Smith GC, Ong WK, Rewcastle GW, Kendall JD, Han W, Shepherd PR. Effects of acutely inhibiting PI3K isoforms and mTOR on regulation of glucose metabolism in vivo. Biochem J 2012;442:161-9.
54. Yap TA, Yan L, Patnaik A, Fearen I, Olmos D, Papadopoulos K, et al. First-in-man clinical trial of the oral pan-AKT inhibitor MK-2206 in patients with advanced solid tumors. J Clin Oncol 2011;29:4688-95.
55. Yan Y, Wagle M, Punnoose E, Musib L, Budha N, Nannini M, et al. A first-in-human trial of GDC-0068: A novel, oral, ATP-competitive Akt inhibitor, demonstrates robust suppression of the Akt pathway in surrogate and tumor tissues. Mol Cancer Ther 2011;10:B154.
56. Saura C, Jones S, Mateo J, Hollebecque A, Cleary JM, Roda Perez D, et al. A phase Ib study of the Akt inhibitor GDC-0068 with docetaxel (D) or mFOLFOX-6 (F) in patients (pts) with advanced solid tumors. J Clin Oncol 30:2012 (suppl; abstr 3021).
57. She QB, Chandarlapaty S, Ye Q, Lobo J, Haskell KM, Leander KR, et al. Breast tumor cells with PI3K mutation or HER2 amplification are selectively addicted to Akt signaling. PLoS ONE 2008;3:e3065.
58. Banerji S, Cibulskis K, Rangel-Escareno C, Brown KK, Carter SL, Frederick AM, et al. Sequence analysis of mutations and translocations across breast cancer subtypes. Nature 2012;486:405-9.
59. Carpten JD, Faber AL, Horn C, Donoho GP, Briggs SL, Robbins CM, et al. A transforming mutation in the pleckstrin homology domain of AKT1 in cancer. Nature 2007;448:439-44.
60. Sangai T, Akcakanat A, Chen H, Tarco E, Wu Y, Do KA, et al. Biomarkers of response to Akt inhibitor MK-2206 in breast cancer. Clin Cancer Res 2012;18:5816-28.
61. Davies BR, Greenwood H, Dudley P, Crafter C, Yu DH, Zhang J, et al. Preclinical pharmacology of AZD5363, an inhibitor of AKT: pharmacodynamics, antitumor activity, and correlation of monotherapy activity with genetic background. Mol Cancer Ther 2012;11:873-87.
62. Lin J, Sampath D, Nannini MA, Lee BB, Degtyarev M, Oeh J, et al. Targeting activated Akt with GDC-0068, a novel selective Akt inhibitor that is efficacious in multiple tumor models. Clin Cancer Res 2013; 19:1760-72.
63. Banerji U, Ranson M, Schellens J, Esaki T, Dean E, Zivi A, et al. Results of two phase I multicenter trials of AZD5363, an inhibitor of AKT1, 2 and 3: Biomarker and early clinical evaluation in Western and Japanese patients with advanced solid tumors. Cancer Res 2013;73:LB-66.
64. Hsieh AC, Liu Y, Edlind MP, Ingolia NT, Janes MR, Sher A, et al. The translational landscape of mTOR signalling steers cancer initiation and metastasis. Nature 2012;485:55-61.
65. Bhagwat SV, Gokhale PC, Crew AP, Cooke A, Yao Y, Mantis C, et al. Preclinical characterization of OSI-027, a potent and selective inhibitor of mTORC1 and mTORC2: distinct from rapamycin. Mol Cancer Ther 2011;10:1394-406.
66. + breast cancer. Cancer Res 2012;72:917.
67. Guo Y, Kwiatkowski DJ. Equivalent benefit of rapamycin and a potent mTOR ATP-competitive inhibitor, MLN0128 (INK128), in a mouse model of tuberous sclerosis. Mol Cancer Res 2013;11:467-73.
68. Banerji U, Dean EJ, Gonzalez M, Greystoke AP, Basu B, Krebs M, et al. First-in-human phase I trial of the dual mTORC1 and mTORC2 inhibitor AZD2014 in solid tumors. J Clin Oncol 30:2012 (suppl; abstr 3004).
69. Varga A, Mita M, Wu J, Nemunaitis J, Cloughesy T, Mischel P, et al. Phase I expansion trial of an oral TORC1/TORC2 inhibitor (CC-223) in advanced solid tumors. J Clin Oncol 31:2013 (suppl; abstr 2606).
70. Shih KC, Bendell JC, Reinert A, Jones S, Kelley RK, Infante JR, et al. Phase I trial of an oral TORC1/TORC2 inhibitor (CC-223) in advanced solid and hematologic cancers. J Clin Oncol 30:2012 (suppl; abstr 3006).
71. Goy A, Ribrag V, Varga A, Witzig T, Ocio E, Paz-Ares L, et al. Phase I expansion trial of an oral TORC1/TORC2 inhibitor (CC-223) in diffuse large B-cell lymphoma (DLBCL) and multiple myeloma (MM). J Clin Oncol 31:2013 (suppl; abstr 8522).
72. Burris HA III. Overcoming acquired resistance to anticancer therapy: focus on the PI3K/AKT/mTOR pathway. Cancer Chemother Pharmacol 2013;71:829-42.
73. Yardley DA, Noguchi S, Pritchard KI, Burris HA III, Baselga J, Gnant M, et al. Everolimus plus exemestane in postmenopausal patients withHR breast cancer: BOLERO-2 final progression-free survival analysis. Adv Ther 2013;30:870-84.
74. O'Regan R, Ozguroglu M, Andre F, Toi M, Heinrich G, Jerusalem M, et al. Phase III, randomized, double-blind, placebo-controlled multicenter trial of daily everolimus plus weekly trastuzumab and vinorelbine in trastuzumab- resistant, advanced breast cancer (BOLERO-3). J Clin Oncol 31:2013 (suppl; abstr 505).
75. Janku F, Wheler JJ, Westin SN, Moulder SL, Naing A, Tsimberidou AM, et al. PI3K/AKT/mTOR inhibitors in patients with breast and gynecologic malignancies harboring PIK3CA mutations. J Clin Oncol 2012;30:777-82.
76. Janku F, Wheler JJ, Naing A, Falchook GS, Hong DS, Stepanek VM, et al. PIK3CA mutation H1047R is associated with response to PI3K/ AKT/mTOR signaling pathway inhibitors in early-phase clinical trials. Cancer Res 2013;73:276-84.
77. Alix-Panabieres C, Pantel K. Technologies for detection of circulating tumor cells: facts and vision. Lab Chip 2014;14:57-62.
78. Maira SM, Stauffer F, Brueggen J, Furet P, Schnell C, Fritsch C, et al. Identification and characterization of NVP-BEZ235, a new orally available dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor with potent in vivo antitumor activity. Mol Cancer Ther 2008;7:1851-63.
79. Knight SD, Adams ND, Burgess JL, Chaudhari AM, Darcy MG, Donatelli CA, et al. Discovery of GSK2126458, a highly potent inhibitor of PI3K and the mammalian target of rapamycin. ACS Med Chem Lett 2010;1:39-43.
80. Mallon R, Feldberg LR, Lucas J, Chaudhary I, Dehnhardt C, Santos ED, et al. Antitumor efficacy of PKI-587, a highly potent dual PI3K/mTOR kinase inhibitor. Clin Cancer Res 2011;17:3193-203.
81. Brana I, LoRusso P, Baselga J, Heath EI, Patnaik A, Gendreau S, et al. A phase I dose-escalation study of the safety, pharmacokinetics (PK), and pharmacodynamics of XL765 (SAR245409), a PI3K/TORC1/ TORC2 inhibitor administered orally to patients (pts) with advanced malignancies. J Clin Oncol 28:15s, 2010 (suppl; abstr 3030).
82. Baselga J, De Jonge MJ, Rodon J, Burris HA, Birle DC, De Buck SS, et al. A first-in-human phase I study of BKM120, an oral pan-class I PI3K inhibitor, in patients (pts) with advanced solid tumors. J Clin Oncol 28:15s, 2010 (suppl; abstr 3003).
83. Edelman G, Bedell C, Shapiro G, Pandya SS, Kwak EL, Scheffold C, et al. A phase I dose-escalation study of XL147 (SAR245408), a PI3K inhibitor administered orally to patients (pts) with advanced malignancies. J Clin Oncol 28:15s, 2010 (suppl; abstr 3004).
84. Folkes AJ, Ahmadi K, Alderton WK, Alix S, Baker SJ, Box G, et al. The identification of 2-(1H-indazol-4-yl)-6-(4-methanesulfonylpiperazin- 1-ylmethyl)-4-morpholin-4-yl-t hieno[3,2-d]pyrimidine (GDC-0941) as a potent, selective, orally bioavailable inhibitor of class I PI3 kinase for the treatment of cancer. J Med Chem 2008;51: 5522-32.
85. Patnaik A, Ramanathan R, Dubowy R, Tolcher A, Papadopoulos K, Beeram M, et al. The evolution of PI3 kinase inhibitors: results of a firstin human phase I study of BAY 80-6946 in patients with advanced solid tumors. Ann Oncol 2012;23:L2. 2.
86. Pitz MW, MacNeil MV, Macdonald DR, Kakumanu AS, Thiessen B, Tsao MS, et al. Phase II study of PX-866 in recurrent glioblastoma. J Clin Oncol 30:2013 (suppl; abstr 2053).